A phase 2 trial from the University of Miami evaluated whether combining iberdomide with carfilzomib, daratumumab, and dexamethasone could induce deep responses—including MRD-negativity—in patients with...
A randomized phase III study evaluated whether a carfilzomib-based triplet regimen could improve depth of response and progression-free survival compared with standard bortezomib-based therapy in patients...
A new real-world study evaluates whether GLP-1 receptor agonists, commonly prescribed for diabetes and obesity, are associated with a reduced risk of progression from monoclonal gammopathy of undetermined...
In a multicenter US study of patients with relapsed/refractory multiple myeloma receiving commercial ciltacabtagene autoleucel, investigators examined whether rapid peak CAR T-cell expansion and absolute...
A new analysis from Western Washington investigators suggests that adverse financial events at diagnosis may delay treatment initiation for patients with hematologic malignancies, highlighting a potential...
